LentiStem Biotech was thrilled to announce its participation in a prestigious event focusing on the future of healthcare through Personalised Medicine. Celebrated on the 4th and 5th of October 2023 in Valencia. LentiStem Biotech has been extended a coveted invitation to showcase its pioneering project on Regulatable 4th generation CAR-T cells for the treatment of HER2+ solid tumors, representing the esteemed consortium FITHER18.
FITHER18, a dynamic public-private consortium, unites top-tier researchers from FIBAO (Prof. Francisco Martin), IdisNA (Dr. Juan Roberto Rodríguez-Madoz), Ciemat (Dra. Rosa María Yánez), together with LentiStem Biotech (Dr. María Tristán). With expertise spanning from fundamental research to clinical trials, this consortium aims to drive forward the frontiers of advanced therapies and CAR-T therapy.
Our project endeavors to develop more controlled, effective, and accessible CAR-T products for solid tumors and being selected to present at this European conference on Personalised Medicine underscores the groundbreaking nature of our research and its potential to significantly impact healthcare.
The European high-level conference, organized by the Spanish Presidency of the Council of the European Union, convened a diverse array of experts and stakeholders to discuss the pivotal role of Personalised Medicine in shaping the future of healthcare and enhancing quality of life. Hosted by the Príncipe Felipe Research Center Foundation (CIPF), the event was coordinated by the Spanish Foundation for Science and Technology (FECYT), on behalf of the Spanish Ministry of Science and Innovation, the Institute of Health Carlos III (ISCIII), and the Centre for the Development of Technology and Innovation (CDTI).
Representatives from LentiStem, including María Tristán, CSO of LentiStem, and Prof. Francisco Martin from FIBAO, attended to showcase the project to various stakeholders, including government ministries and patient associations, with the shared vision of advancing healthcare through innovative medical breakthroughs.
This project is finantially supported by the call Actuación Conjunta ISCIII-CDTI: Innovaciones en Medicina Personalizada y Terapias Avanzadas 2022.
No responses yet